Abstract
Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have